November 18, 2025 — Leads & Copy —
TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) has announced the listing of its common shares on the Frankfurt Stock Exchange (FSE) under the trading symbol “9DY.” The company has also retained bullVestor Medien GmbH to provide marketing services for three months, starting November 18, 2025.
The Frankfurt Stock Exchange, one of the world’s largest and most liquid trading venues, offers access to a wide base of institutional and retail investors across Europe. The listing is a significant step in expanding TempraMed’s visibility and strengthening its international presence. The company expects the FSE listing to increase trading liquidity and broaden engagement with European investors, particularly in a region known for its focus on healthcare innovation and rapid adoption of medical technologies.
TempraMed CEO Ron Nagar stated that listing on the Frankfurt Stock Exchange represents a significant milestone as the company expands its presence in the European capital markets. He added that TempraMed is committed to fostering strong relationships with European investors and believes this listing will help the company achieve greater visibility and liquidity across the region.
Under the marketing services agreement, bullVestor will create content, ad groups, and display ads, as well as provide keyword optimization, project management, and media distribution services, to increase awareness of TempraMed’s business. TempraMed will pay bullVestor a total fee of €130,000 (approximately CAD $210,000), paid in two installments: €75,000 (approximately CAD $120,000) within seven days after the agreement date, and €55,000 (approximately CAD $90,000) within 30 days after the agreement date.
At the time of entering into the agreement, bullVestor and its principals did not own any common shares or other securities of TempraMed Technologies Ltd.
TempraMed CEO Ron Nagar stated that the company is excited to partner with bullVestor, a renowned marketing firm in Europe, to enhance its engagement with the investment community. He believes bullVestor will amplify TempraMed’s presence in the market as the company effectively communicates its story to investors.
TempraMed Technologies Ltd. is a global leader in innovative, temperature-controlled medication storage solutions. The company develops patented, FDA-registered, space-grade thermal insulation devices that work 24/7 without charging or external power. Its product line includes VIVI Cap and VIVI Epi, and a smart technology platform is on the horizon. TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe, and Asia, TempraMed is advancing the future of medication protection and adherence.
The Frankfurt Stock Exchange, operated by Deutsche Börse AG, is one of the world’s largest securities trading venues and a key financial hub for European and international investors. With a market capitalization exceeding $2 trillion USD, the FSE ranks among the top global exchanges and provides access to both institutional and retail investors. It is a preferred listing destination for innovative technology and industrial companies seeking to expand their global investor base.
Investors interested learning more about TempraMed are encouraged to contact the Company at: ir@tempramed.com
Investor Contacts:
Julia Becker
Vice President, Capital Markets
T: +1 (604) 785-0850
E: julia@tempramed.com
Ron Nagar
Chief Executive Officer
TempraMed Technologies Ltd.
ir@tempramed.com
Source: TempraMed Technologies Ltd.
